Results for tag: "Endothelial Dysfunction Drug"

The Endothelial Dysfunction Drug market is a subset of the Cardiovascular Drugs market, focusing on drugs that target endothelial dysfunction. Endothelial dysfunction is a condition in which the endothelium, the inner lining of the blood vessels, does not function properly. This can lead to a variety of cardiovascular diseases, including hypertension, coronary artery disease, and stroke. Endothelial dysfunction drugs are designed to improve the function of the endothelium, thereby reducing the risk of cardiovascular disease. These drugs are typically administered orally or intravenously, and may include angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, and nitrates. They are often used in combination with lifestyle modifications, such as diet and exercise, to reduce the risk of cardiovascular disease. Some companies in the Endothelial Dysfunction Drug market include Pfizer, Merck, Novartis, Sanofi, and AstraZeneca. Show Less Read more